Horizon Funds - Horizon Flexible Income ETF
US ˙ BATS ˙ US33938J1060

Introduction

This page provides a comprehensive analysis of the known insider trading history of Heath Lukatch. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Heath Lukatch has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:PCVX / Vaxcyte, Inc. Director 17,216
US:FLXN / Horizon Funds - Horizon Flexible Income ETF Director 0
US:INGN / Inogen, Inc. Director 12,775
US:STSA / Satsuma Pharmaceuticals Inc Director 20,000
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Heath Lukatch. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases FLXN / Horizon Funds - Horizon Flexible Income ETF - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in FLXN / Horizon Funds - Horizon Flexible Income ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FLXN / Horizon Funds - Horizon Flexible Income ETF Insider Trades
Insider Sales FLXN / Horizon Funds - Horizon Flexible Income ETF - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in FLXN / Horizon Funds - Horizon Flexible Income ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

FLXN / Horizon Funds - Horizon Flexible Income ETF Insider Trades
Insider Purchases INGN / Inogen, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in FLXN / Horizon Funds - Horizon Flexible Income ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2019-08-15 INGN Lukatch Heath 2,000 43.0100 2,000 43.0100 86,020 102 76.1500 66,280 77.05

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INGN / Inogen, Inc. Insider Trades
Insider Sales INGN / Inogen, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in FLXN / Horizon Funds - Horizon Flexible Income ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2018-08-06 INGN Lukatch Heath 100 212.3000 100 212.3000 21,230 365 55.1800 -15,712 -74.01
2017-05-30 INGN Lukatch Heath 1,754 88.3000 1,754 88.3000 154,878
2017-05-26 INGN Lukatch Heath 7,246 88.5682 7,246 88.5682 641,765

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

INGN / Inogen, Inc. Insider Trades
Insider Purchases PCVX / Vaxcyte, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in FLXN / Horizon Funds - Horizon Flexible Income ETF. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCVX / Vaxcyte, Inc. Insider Trades
Insider Sales PCVX / Vaxcyte, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in FLXN / Horizon Funds - Horizon Flexible Income ETF. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

PCVX / Vaxcyte, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Heath Lukatch as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-06-16 2025-06-12 4 PCVX Vaxcyte, Inc.
Common Stock
A - Award 3,041 17,216 21.45
2025-04-10 2025-04-08 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 1,000 14,175 7.59 21.49 21,490 304,621
2025-04-10 2025-04-08 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 6,000 13,175 83.62 16.00 96,000 210,800
2024-06-10 2024-06-06 4 PCVX Vaxcyte, Inc.
Common Stock
A - Award 1,550 7,175 27.56
2024-02-02 2024-01-31 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -5,000 5,625 -47.06 71.50 -357,500 402,188
2024-02-02 2024-01-31 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 5,000 10,625 88.89 16.00 80,000 170,000
2024-01-31 2024-01-29 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -4,000 5,625 -41.56 67.50 -270,000 379,688
2024-01-31 2024-01-29 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 4,000 9,625 71.11 16.00 64,000 154,000
2024-01-04 2024-01-02 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -291 5,625 -4.92 65.19 -18,971 366,705
2024-01-04 2024-01-02 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -4,164 5,916 -41.31 64.28 -267,662 380,280
2024-01-04 2024-01-02 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -7,444 10,080 -42.48 63.55 -473,081 640,604
2024-01-04 2024-01-02 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -1,101 17,524 -5.91 62.85 -69,201 1,101,436
2024-01-04 2024-01-02 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 13,000 18,625 231.11 16.00 208,000 298,000
2023-06-15 2023-06-13 4 PCVX Vaxcyte, Inc.
Common Stock
A - Award 2,500 5,625 80.00
2023-01-12 2023-01-10 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -82 3,125 -2.56 46.33 -3,799 144,773
2023-01-12 2023-01-10 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -233 3,207 -6.77 46.04 -10,728 147,654
2023-01-12 2023-01-10 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 315 3,440 10.08 16.00 5,040 55,040
2022-12-14 2022-12-12 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -319 3,125 -9.26 44.01 -14,039 137,532
2022-12-14 2022-12-12 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -16 3,444 -0.46 42.36 -678 145,905
2022-12-14 2022-12-12 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 335 3,460 10.72 16.00 5,360 55,360
2022-11-15 2022-11-10 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -4,000 3,125 -56.14 46.25 -185,000 144,531
2022-11-15 2022-11-10 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -335 7,125 -4.49 44.74 -14,989 318,787
2022-11-15 2022-11-10 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 4,335 7,460 138.72 16.00 69,360 119,360
2022-10-26 2022-10-26 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -4,000 3,125 -56.14 38.25 -153,000 119,531
2022-10-26 2022-10-26 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 4,000 7,125 128.00 16.00 64,000 114,000
2022-10-26 2022-10-24 4 PCVX Vaxcyte, Inc.
Common Stock
S - Sale X -3,015 3,125 -49.10 35.11 -105,857 109,719
2022-10-26 2022-10-24 4 PCVX Vaxcyte, Inc.
Common Stock
M - Exercise 3,015 6,140 96.48 16.00 48,240 98,240
2022-06-03 2022-06-01 4 PCVX Vaxcyte, Inc.
Common Stock
A - Award 3,125 3,125
2021-11-19 2021-11-19 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
D - Sale to Issuer -7,000 0 -100.00
2021-11-19 2021-11-19 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
D - Sale to Issuer -7,000 0 -100.00
2021-11-19 2021-11-19 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
D - Sale to Issuer -12,500 0 -100.00
2021-11-19 2021-11-19 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
D - Sale to Issuer -12,500 0 -100.00
2021-11-19 2021-11-19 4 FLXN Flexion Therapeutics Inc
Stock option (right to buy)
D - Sale to Issuer -9,000 0 -100.00
2021-11-19 2021-11-19 4 FLXN Flexion Therapeutics Inc
Common Stock
D - Sale to Issuer -9,000 0 -100.00 8.50 -76,500
2021-06-28 2021-06-24 4 FLXN Flexion Therapeutics Inc
Stock Option (Right to Buy)
A - Award 7,000 7,000
2021-06-28 2021-06-24 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 4,500 9,000 100.00
2021-06-03 2021-06-02 4 PCVX Vaxcyte, Inc.
Stock Option (right to buy)
A - Award -15,000 15,000 -50.00
2021-05-12 2021-05-10 4 INGN Inogen Inc
Common Stock
A - Award 2,754 12,775 27.48
2020-12-07 2020-12-03 4 STSA Satsuma Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 20,000 20,000
2020-06-30 2020-06-29 4 STSA Satsuma Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 20,000 20,000
2020-06-16 2020-06-12 4 STSA Satsuma Pharmaceuticals, Inc.
Stock Option (Right to Buy)
A - Award 10,000 10,000
2020-06-15 2020-06-11 4 PCVX Vaxcyte, Inc.
Stock Option (right to buy)
A - Award 40,000 40,000
2020-06-12 2020-06-10 4 FLXN Flexion Therapeutics Inc
Stock Option (Right to Buy)
A - Award 7,000 7,000
2020-06-12 2020-06-10 4 FLXN Flexion Therapeutics Inc
Common Stock
A - Award 4,500 4,500
2020-05-12 2020-05-11 4 INGN Inogen Inc
Common Stock
A - Award 4,540 10,021 82.83
2019-08-19 2019-08-15 4 INGN Inogen Inc
Common Stock
P - Purchase 2,000 5,481 57.45 43.01 86,020 235,738
2019-05-21 2019-05-09 4/A INGN Inogen Inc
Common Stock
A - Award 2,492 3,481 251.97
2019-05-10 2019-05-09 4 INGN Inogen Inc
Common Stock
A - Award 2,474 3,463 250.15
2018-11-08 2018-11-06 4 INGN Inogen Inc
Stock Option (Right to Buy)
M - Exercise -500 6,665 -6.98
2018-11-08 2018-11-06 4 INGN Inogen Inc
Common Stock
S - Sale X -100 989 -9.18 196.82 -19,682 194,655
2018-11-08 2018-11-06 4 INGN Inogen Inc
Common Stock
S - Sale X -100 1,089 -8.41 195.07 -19,507 212,431
2018-11-08 2018-11-06 4 INGN Inogen Inc
Common Stock
S - Sale X -300 1,189 -20.15 192.66 -57,798 229,073
2018-11-08 2018-11-06 4 INGN Inogen Inc
Common Stock
M - Exercise 500 1,489 50.56 43.21 21,605 64,340
2018-10-09 2018-10-05 4 INGN Inogen Inc
Stock Option (Right to Buy)
M - Exercise -500 7,165 -6.52
2018-10-09 2018-10-05 4 INGN Inogen Inc
Common Stock
S - Sale X -10 989 -1.00 220.56 -2,206 218,134
2018-10-09 2018-10-05 4 INGN Inogen Inc
Common Stock
S - Sale X -130 999 -11.51 219.17 -28,493 218,954
2018-10-09 2018-10-05 4 INGN Inogen Inc
Common Stock
S - Sale X -260 1,129 -18.72 218.85 -56,902 247,086
2018-10-09 2018-10-05 4 INGN Inogen Inc
Common Stock
S - Sale X -20 1,389 -1.42 216.49 -4,330 300,705
2018-10-09 2018-10-05 4 INGN Inogen Inc
Common Stock
S - Sale X -40 1,409 -2.76 215.28 -8,611 303,322
2018-10-09 2018-10-05 4 INGN Inogen Inc
Common Stock
S - Sale X -40 1,449 -2.69 214.34 -8,574 310,575
2018-10-09 2018-10-05 4 INGN Inogen Inc
Common Stock
M - Exercise 500 1,489 50.56 43.21 21,605 64,340
2018-09-07 2018-09-06 4 INGN Inogen Inc
Stock Option (Right to Buy)
M - Exercise -500 7,665 -6.12
2018-09-07 2018-09-06 4 INGN Inogen Inc
Common Stock
S - Sale X -195 989 -16.47 262.70 -51,226 259,808
2018-09-07 2018-09-06 4 INGN Inogen Inc
Common Stock
S - Sale X -305 1,184 -20.48 260.80 -79,544 308,787
2018-09-07 2018-09-06 4 INGN Inogen Inc
Common Stock
M - Exercise 500 1,489 50.56 43.21 21,605 64,340
2018-08-08 2018-08-06 4 INGN Inogen Inc
Stock Option (Right to Buy)
M - Exercise -500 8,165 -5.77
2018-08-08 2018-08-06 4 INGN Inogen Inc
Common Stock
S - Sale -100 989 -9.18 212.30 -21,230 209,965
2018-08-08 2018-08-06 4 INGN Inogen Inc
Common Stock
S - Sale X -400 1,089 -26.86 210.51 -84,204 229,247
2018-08-08 2018-08-06 4 INGN Inogen Inc
Common Stock
M - Exercise 500 1,489 50.56 43.21 21,605 64,340
2018-07-10 2018-07-06 4 INGN Inogen Inc
Stock Option (Right to Buy)
M - Exercise -500 8,665 -5.46
2018-07-10 2018-07-06 4 INGN Inogen Inc
Common Stock
S - Sale X -500 989 -33.58 193.66 -96,830 191,530
2018-07-10 2018-07-06 4 INGN Inogen Inc
Common Stock
M - Exercise 500 1,489 50.56 43.21 21,605 64,340
2018-06-08 2018-06-06 4 INGN Inogen Inc
Stock Option (Right to Buy)
M - Exercise -500 9,165 -5.17
2018-06-08 2018-06-06 4 INGN Inogen Inc
Common Stock
S - Sale X -500 989 -33.58 190.58 -95,290 188,484
2018-06-08 2018-06-06 4 INGN Inogen Inc
Common Stock
M - Exercise 500 1,489 50.56 43.21 21,605 64,340
2018-05-14 2018-05-10 4 INGN Inogen Inc
Common Stock
A - Award 989 989
2018-03-02 2018-03-01 4 INGN Inogen Inc
Stock Option (right to buy)
M - Exercise -2,500 9,665 -20.55
2018-03-02 2018-03-01 4 INGN Inogen Inc
Common Stock
S - Sale X -300 0 -100.00 121.16 -36,349
2018-03-02 2018-03-01 4 INGN Inogen Inc
Common Stock
S - Sale X -1,266 300 -80.84 119.30 -151,031 35,789
2018-03-02 2018-03-01 4 INGN Inogen Inc
Common Stock
S - Sale X -934 1,566 -37.36 118.31 -110,505 185,279
2018-03-02 2018-03-01 4 INGN Inogen Inc
Common Stock
M - Exercise 2,500 2,500 43.21 108,025 108,025
2017-12-05 2017-12-01 4 INGN Inogen Inc
Stock Option (right to buy)
M - Exercise -2,500 12,165 -17.05
2017-12-05 2017-12-01 4 INGN Inogen Inc
Common Stock
S - Sale X -500 0 -100.00 127.28 -63,640
2017-12-05 2017-12-01 4 INGN Inogen Inc
Common Stock
S - Sale X -2,000 500 -80.00 126.18 -252,359 63,090
2017-12-05 2017-12-01 4 INGN Inogen Inc
Common Stock
M - Exercise 2,500 2,500 43.21 108,025 108,025
2017-09-08 2017-09-06 4 INGN Inogen Inc
Stock Option (right to buy)
M - Exercise -2,500 14,665 -14.56
2017-09-08 2017-09-06 4 INGN Inogen Inc
Common Stock
S - Sale X -2,500 0 -100.00 97.44 -243,598
2017-09-08 2017-09-06 4 INGN Inogen Inc
Common Stock
M - Exercise 2,500 2,500 43.21 108,025 108,025
2017-07-27 2017-06-22 4 FLXN Flexion Therapeutics Inc
Stock Option (Right to Buy)
A - Award 12,500 12,500
2017-05-31 2017-05-30 4 INGN Inogen Inc
Stock Option (right to buy)
M - Exercise -1,754 17,165 -9.27
2017-05-31 2017-05-30 4 INGN Inogen Inc
Common Stock
S - Sale -1,754 0 -100.00 88.30 -154,878
2017-05-31 2017-05-30 4 INGN Inogen Inc
Common Stock
M - Exercise 1,754 1,754 43.21 75,790 75,790
2017-05-31 2017-05-26 4 INGN Inogen Inc
Stock Option (right to buy)
M - Exercise -7,246 18,919 -27.69
2017-05-31 2017-05-26 4 INGN Inogen Inc
Common Stock
S - Sale -7,246 0 -100.00 88.57 -641,765
2017-05-31 2017-05-26 4 INGN Inogen Inc
Common Stock
M - Exercise 7,246 7,246 43.21 313,100 313,100
2017-05-12 2017-05-11 4 INGN Inogen Inc
Stock Option (right to buy)
A - Award 12,832 12,832
2016-06-22 2016-06-10 4/A FLXN Flexion Therapeutics Inc
Stock Option (Right to Buy)
A - Award 12,500 12,500
2016-06-13 2016-06-10 4 FLXN Flexion Therapeutics Inc
Stock Option (Right to Buy)
A - Award 12,500 12,500
2016-05-13 2016-05-12 4 INGN Inogen Inc
Stock Option (right to buy)
A - Award 12,832 12,832
2015-10-15 2015-10-14 4 INGN Inogen Inc
Stock Option (right to buy)
A - Award 26,165 26,165
2015-06-19 2015-06-17 4 FLXN Flexion Therapeutics Inc
Stock Option (Right to Buy)
A - Award 9,000 9,000
2014-02-12 3 INGN Inogen Inc
No securities beneficially owned or held.
0
2014-02-11 3 FLXN Flexion Therapeutics Inc
No securities are beneficially owned.
0
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)